Skip to Content

Wynzora Approval Status

FDA Approved: No
Brand name: Wynzora
Generic name: calcipotriene and betamethasone dipropionate
Dosage form: Cream
Company: MC2 Therapeutics
Treatment for: Plaque Psoriasis

Wynzora (calcipotriene 0.005% and betamethasone dipropionate 0.064%) is a PADâ„¢ Cream formulation of calcipotriene and betamethasone dipropionate in development as a more convenient alternative to similar existing products for the topical treatment of plaque psoriasis.

Development Status and FDA Approval Process for Wynzora

DateArticle
Sep 24, 2019MC2 Therapeutics Announces Submission of NDA for Wynzora Cream (Calcipotriene 0.005% and Betamethasone Dipropionate 0.064%) for Treatment of Plaque Psoriasis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide